Summary & Overview
CPT 52356: Cystourethroscopy with Ureteroscopy, Lithotripsy, and Stent Placement
CPT code 52356 is a key billing code in urology, representing cystourethroscopy with ureteroscopy and/or pyeloscopy, lithotripsy, and insertion of an indwelling ureteral stent. This procedure is widely used for the management of urinary tract stones and is performed in surgical settings such as hospital outpatient departments and ambulatory surgery centers. Nationally, this code is recognized by major payers including Aetna, Blue Cross Blue Shield, Cigna Health, Medicare, and UnitedHealthcare, ensuring broad coverage for patients requiring advanced urinary stone treatment.
This publication provides a comprehensive overview of CPT 52356, including payer coverage, clinical context, and related coding benchmarks. Readers will gain insight into the procedural details, typical sites of service, and the importance of this code in modern urologic practice. Policy updates, reimbursement trends, and clinical indications are also discussed, offering a clear understanding of how this code fits into the broader landscape of surgical urinary system procedures. The analysis includes comparisons to related CPT codes and highlights the role of CPT 52356 in facilitating minimally invasive treatment options for urinary stones.
CPT Code Overview
CPT 52356 describes a surgical procedure in urology involving cystourethroscopy with ureteroscopy and/or pyeloscopy, combined with lithotripsy and the insertion of an indwelling ureteral stent, such as a Gibbons or double‑J type. This procedure is typically performed to treat urinary stones and facilitate drainage in the urinary system. The most common sites of service for this procedure are hospital outpatient departments or ambulatory surgery centers, corresponding to place of service codes POS 19 or 24. This code is central to surgical management of urinary tract stones and related conditions, reflecting advanced endoscopic techniques in urology.
Clinical & Coding Specifications
Clinical Context
A typical patient scenario involves an adult presenting with symptoms such as flank pain, hematuria, or dysuria. Imaging studies reveal a urinary stone located in the ureter or kidney. The patient is scheduled for a surgical procedure in a hospital outpatient department or ambulatory surgery center (place of service 19 or 24). The urologist performs a cystourethroscopy with ureteroscopy and/or pyeloscopy, uses lithotripsy to fragment the stone, and inserts an indwelling ureteral stent (such as a Gibbons or double-J type) to ensure patency of the ureter post-procedure. This workflow is typical for management of urinary calculi that require endoscopic intervention and stenting.
Coding Specifications
-
Modifier
51: Indicates multiple procedures were performed during the same session. Used when more than one surgical procedure is completed. -
Modifier
59: Denotes a distinct procedural service. Used when procedures are not normally reported together but are appropriate due to different sites or circumstances.
| Provider Taxonomy Code | Specialty Name |
|---|---|
208800000X | Urology Physician |
2088P0231X | Pediatric Urology Physician |
2088F0040X | Female Pelvic Medicine and Reconstructive Surgery Physician |
Related Diagnoses
-
N20.0- Calculus of kidney- Indicates the presence of a kidney stone, which may require endoscopic removal and stenting.
-
N20.1- Calculus of ureter- Refers to a stone located in the ureter, often managed with ureteroscopy, lithotripsy, and stent placement.
-
N20.2- Calculus of kidney with calculus of ureter- Represents stones in both the kidney and ureter, potentially necessitating comprehensive endoscopic intervention.
-
N20.9- Urinary calculus, unspecified- Used when the location of the urinary stone is not specified, but endoscopic management is indicated.
-
R30.0- Dysuria- Symptom code for painful urination, which may be associated with urinary stones and justify the procedure.
Related CPT Codes
-
52351: Cystourethroscopy, with ureteroscopy and/or pyeloscopy; diagnostic- Used for diagnostic endoscopic evaluation of the urinary tract. May precede therapeutic procedures such as those coded with
52356.
- Used for diagnostic endoscopic evaluation of the urinary tract. May precede therapeutic procedures such as those coded with
-
52353: Cystourethroscopy, with ureteroscopy and/or pyeloscopy; with lithotripsy (fragments pass or washed out)- Used when lithotripsy is performed but no stent is placed. Can be an alternative to
52356if stenting is not required.
- Used when lithotripsy is performed but no stent is placed. Can be an alternative to
-
52354: Cystourethroscopy, with ureteroscopy and/or pyeloscopy; lesion biopsy or fulguration- Used for biopsy or fulguration of lesions during endoscopic procedures. May be performed in conjunction with stone management procedures.
These codes are related in the clinical workflow as diagnostic (52351), therapeutic without stent (52353), and therapeutic with stent (52356). Codes may be used together or as alternatives depending on the clinical scenario.
National Reimbursement Benchmarks
Nationally, Medicare's mean rate for CPT 52356 is $370.35, which is substantially lower than the BUCA (Blue Cross Blue Shield, UnitedHealth Group, Cigna, and Aetna) commercial average of $627.22. Commercial payers consistently reimburse at higher levels compared to Medicare, with UnitedHealth Group showing the highest mean rate at $740.73.
Rate dispersion varies across payers. Medicare has the tightest range between the 25th and 75th percentiles ($21.00), indicating minimal variation in payment. In contrast, UnitedHealth Group exhibits the widest spread ($426.00), followed by Cigna ($370.00), reflecting greater variability in commercial reimbursement. The table and chart below present the full breakdown of national benchmarks for each payer.
State Benchmarks
State: AK1 / 50
Alaska Benchmarks
Alaska exhibits a wide spread in reimbursement rates for CPT code 52356, with the highest commercial payer (Aetna) mean rate at $2,074.89 and the lowest (Cigna) at $838.79. The rate spread, measured by the difference between the 75th and 25th percentiles, is most pronounced for BUCA ($572.14), followed by Cigna ($565.80), and BCBS ($327.75). This indicates significant variability in commercial payer reimbursement within the state. Medicare's rate spread is much narrower at $24.00, reflecting more consistent government rates.
Compared to national averages, Alaska's commercial payers consistently reimburse at much higher rates, with Aetna's mean rate more than triple the national benchmark. The table and chart below present the full breakdown of payer-specific rates, highlighting the substantial differences between payers and the elevated reimbursement environment in Alaska.
Key Insights for Alaska
- Aetna is the highest paying payer in Alaska for CPT 52356, with a mean rate of $2,074.89.
- Medicare is the lowest paying payer, with a mean rate of $366.84, significantly below all commercial payers.
- All commercial payers in Alaska reimburse at rates well above their respective national averages, with Aetna's mean rate more than triple its national benchmark.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.